Related Posts
Biocon Biologics’ Yesafili to enter US market, after agreement with Regeneron
- staff
- April 15, 2025
- 0
Biocon Biologics has reached a settlement with Regeneron, allowing the launch of Yesafili, its biosimilar eye drug, in the US by the second half of […]
Is the world staring at a recession? ‘There will be blood’, warn experts on Donald Trump’s reciprocal tariffs impact
- staff
- April 4, 2025
- 0
Economic forecasts show growing recession fears as Donald Trump’s new tariff announcements dampen global business sentiment and disrupt supply chains. Major financial institutions like JPMorgan […]
H-1B visas: Are TCS, Infosys susceptible to US’ immigration policy changes? Here’s what Moody’s says
- staff
- March 19, 2025
- 0
Moody’s has said that changes in US H-1B visa policy put major Indian IT firms at risk due to immigration policy shifts and rising costs. […]